CC-10004 .
CC-10004, a phosphodiesterase 4 inhibitor and selective cytokine inhibitor, is under development by Celgene for the potential treatment of asthma, chronic obstructive pulmonary disease, inflammation and psoriasis. By October 2004, phase II trials in psoriasis had commenced.
Khobzaoui
Moussa
M
Synovo GmbH, Paul Ehrlich Strasse 15, D-72076 Tubingen, Germany.
Gutke
Hans-Jürgen
HJ
Burnet
Michael
M
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001249:Asthma / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy
D016207:Cytokines; D010726:Phosphodiesterase Inhibitors; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4